-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $141

Benzinga·07/07/2026 16:21:13
Listen to the news
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $137 to $141.